Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-term testosterone replacement in testicular cancer survivors with overweight
NL-OMON50478Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in Hypoandrogenism (TD), cardiometabolic risk (CMR) and Overweight comparing Androgel then Androgel with Placebo then Androgel (2 arms). Primary endpoint: Change in fat mass at 20 weeks. Started Dec 2018; status: recruiting.
02
Drugs
testosterone
03
Conditions
Hypoandrogenism (TD)cardiometabolic risk (CMR)Overweight
Beyond the preview
Go deeper on NL-OMON50478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50478.